Symbols / CRNX Stock $37.48 +1.54% Crinetics Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
CRNX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. R. Scott Struthers Ph.D.
Exch · Country NMS · United States
Market Cap 3.95B
Enterprise Value 2.65B
Income -496.39M
Sales 18.07M
FCF (ttm) -242.14M
Book/sh 12.16
Cash/sh 12.25
Employees 594
Insider 10d —
IPO Jul 18, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.95
PEG —
P/S 218.71
P/B 3.08
P/C —
EV/EBITDA -4.89
EV/Sales 146.57
Quick Ratio 18.25
Current Ratio 18.60
Debt/Eq 3.74
LT Debt/Eq —
EPS (ttm) -5.14
EPS next Y -4.19
EPS Growth —
Revenue Growth 28.73%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -24.69%
ROE -39.17%
ROIC —
Gross Margin 0.00%
Oper. Margin -13.08%
Profit Margin 0.00%
Shs Outstand 105.44M
Shs Float 96.99M
Insider Own 1.59%
Instit Own 110.94%
Short Float 15.74%
Short Ratio 12.96
Short Interest 14.17M
52W High 57.99
vs 52W High -35.37%
52W Low 25.83
vs 52W Low 45.10%
Beta 0.28
Impl. Vol. 68.65%
Rel Volume 0.95
Avg Volume 1.20M
Volume 1.14M
Target (mean) $83.21
Tgt Median $86.50
Tgt Low $55.00
Tgt High $97.00
# Analysts 14
Recom Strong_buy
Prev Close $36.91
Price $37.48
Change 1.54%
About

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$83.21
Mean price target
2. Current target
$37.48
Latest analyst target
3. DCF / Fair value
$-41.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$37.48
Low
$55.00
High
$97.00
Mean
$83.21

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main Oppenheimer Outperform → Outperform $84
2026-05-08 main Citizens Market Outperform → Market Outperform $95
2026-04-28 main Citizens Market Outperform → Market Outperform $97
2026-03-02 main Citizens Market Outperform → Market Outperform $96
2026-01-12 up Goldman Sachs Neutral → Buy $67
2026-01-08 main Citizens Market Outperform → Market Outperform $105
2026-01-06 main Morgan Stanley Overweight → Overweight $80
2025-11-07 main Citizens Market Outperform → Market Outperform $108
2025-09-30 main Oppenheimer Outperform → Outperform $87
2025-09-29 main Morgan Stanley Overweight → Overweight $77
2025-09-29 main Leerink Partners Outperform → Outperform $88
2025-09-26 main Goldman Sachs Neutral → Neutral $40
2025-09-26 main JMP Securities Market Outperform → Market Outperform $143
2025-09-26 main Baird Outperform → Outperform $62
2025-09-24 main JP Morgan Overweight → Overweight $52
2025-08-11 main JMP Securities Market Outperform → Market Outperform $86
2025-06-27 reit HC Wainwright & Co. Buy → Buy $81
2025-03-25 init Stifel — → Buy $60
2025-02-28 main Citizens Capital Markets Market Outperform → Market Outperform $91
2025-02-04 init Wolfe Research — → Peer Perform —
News
RSS: Latest CRNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-08 KNIGHT JEFF E Chief Operating Officer — 78,434 $19.64 $1,758,818
2026-04-08 KNIGHT JEFF E Chief Operating Officer — 85,163 $40.10 $3,415,036
2026-03-16 STRUTHERS RICHARD SCOTT Chief Executive Officer — 21,981 $37.11 $821,513
2026-03-16 KNIGHT JEFF E Chief Operating Officer — 9,911 $37.11 $370,411
2026-03-16 BETZ STEPHEN F Officer — 10,612 $37.11 $396,610
2026-03-12 VIVALDI COELHO ROGERIO Director — 5,000 $36.08 $180,761
2026-03-03 SCHILKE TOBIN Chief Financial Officer — 6,713 $39.67 $266,305
2026-03-03 OKEY STEPHANIE S Director — 3,000 $39.67 $119,010
2026-02-23 SCHILKE TOBIN Chief Financial Officer — 32,000 $0.00 $0
2026-02-23 STRUTHERS RICHARD SCOTT Chief Executive Officer — 62,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
7.70
+640.71%
1.04
-74.11%
4.01
-15.28%
4.74
Operating Revenue
7.70
+640.71%
1.04
-74.11%
4.01
-15.28%
4.74
Cost Of Revenue
1.08
0.00
0.00
—
Reconciled Cost Of Revenue
1.08
0.00
0.00
—
Gross Profit
6.62
+537.15%
1.04
-74.11%
4.01
—
Operating Expense
523.39
+53.99%
339.89
+49.98%
226.62
+31.28%
172.62
Research And Development
332.06
+38.27%
240.16
+42.50%
168.53
+29.41%
130.22
Selling General And Administration
191.33
+91.84%
99.74
+71.68%
58.09
+37.03%
42.39
General And Administrative Expense
191.33
+91.84%
99.74
+71.68%
58.09
+37.03%
42.39
Other Gand A
191.33
+91.84%
99.74
+71.68%
58.09
+37.03%
42.39
Total Expenses
524.47
+54.30%
339.89
+49.98%
226.62
+31.28%
172.62
Operating Income
-516.77
-52.50%
-338.85
-52.22%
-222.61
-32.60%
-167.88
Total Operating Income As Reported
-516.77
-52.50%
-338.85
-52.22%
-222.61
-32.60%
-167.88
EBITDA
-512.88
-52.61%
-336.07
-51.72%
-221.51
-32.72%
-166.90
Normalized EBITDA
-512.88
-52.61%
-336.07
-51.72%
-221.51
-32.25%
-167.50
Reconciled Depreciation
3.89
+39.68%
2.79
+153.64%
1.10
+11.70%
0.98
EBIT
-516.77
-52.50%
-338.85
-52.22%
-222.61
-32.60%
-167.88
Total Unusual Items
—
—
—
0.60
Total Unusual Items Excluding Goodwill
—
—
—
0.60
Net Income
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Pretax Income
-465.14
-55.87%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Net Non Operating Interest Income Expense
51.99
+25.47%
41.44
+208.39%
13.44
+211.23%
4.32
Net Interest Income
51.99
+25.47%
41.44
+208.39%
13.44
+211.23%
4.32
Interest Income Non Operating
51.99
+25.47%
41.44
+208.39%
13.44
+211.23%
4.32
Interest Income
51.99
+25.47%
41.44
+208.39%
13.44
+211.23%
4.32
Other Income Expense
-0.36
+63.90%
-0.99
+81.54%
-5.36
-1417.56%
-0.35
Other Non Operating Income Expenses
-0.36
+31.21%
-0.52
-226.42%
-0.16
-378.95%
0.06
Gain On Sale Of Security
—
—
—
0.60
Tax Provision
0.18
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Net Income From Continuing Operation Net Minority Interest
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Net Income From Continuing And Discontinued Operation
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Net Income Continuous Operations
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Normalized Income
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.40%
-164.52
Net Income Common Stockholders
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Diluted EPS
—
-3.69
+0.00%
-3.69
-17.14%
-3.15
Basic EPS
—
-3.69
+0.00%
-3.69
-17.14%
-3.15
Basic Average Shares
—
80.78
+39.11%
58.07
+11.71%
51.98
Diluted Average Shares
—
80.78
+39.11%
58.07
+11.71%
51.98
Diluted NI Availto Com Stockholders
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Earnings From Equity Interest
0.00
+100.00%
-0.47
+90.96%
-5.20
-414.65%
-1.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,126.26
-21.49%
1,434.59
+125.79%
635.35
+80.41%
352.18
Current Assets
1,048.34
-23.78%
1,375.39
+139.55%
574.15
+66.33%
345.18
Cash Cash Equivalents And Short Term Investments
1,027.89
-24.09%
1,354.07
+142.42%
558.55
+67.02%
334.43
Cash And Cash Equivalents
101.54
-61.62%
264.55
+381.89%
54.90
+68.02%
32.67
Other Short Term Investments
926.35
-14.98%
1,089.52
+116.32%
503.66
+66.91%
301.75
Receivables
0.59
0.00
-100.00%
9.35
+208.61%
3.03
Accounts Receivable
0.59
0.00
—
—
Other Receivables
—
0.09
-98.43%
5.46
+802.98%
0.60
Taxes Receivable
—
0.07
-90.09%
0.75
-20.28%
0.94
Accrued Interest Receivable
—
8.31
+172.37%
3.05
+125.50%
1.35
Inventory
2.02
0.00
—
—
Prepaid Assets
—
11.14
+92.14%
5.80
+0.00%
5.80
Restricted Cash
0.00
-100.00%
0.50
0.00
—
Other Current Assets
17.84
-14.31%
20.82
+4547.10%
0.45
-76.79%
1.93
Total Non Current Assets
77.92
+31.60%
59.20
-3.26%
61.20
+775.29%
6.99
Net PPE
54.79
-1.42%
55.58
-3.23%
57.43
+1051.83%
4.99
Gross PPE
62.74
-0.90%
63.31
+1.29%
62.50
+589.06%
9.07
Accumulated Depreciation
-7.95
-2.85%
-7.73
-52.57%
-5.07
-24.09%
-4.08
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.29
+3.53%
2.21
+18.72%
1.86
+106.56%
0.90
Other Properties
50.45
+2.54%
49.20
-3.15%
50.80
+991.58%
4.65
Leases
10.00
-15.94%
11.90
+20.97%
9.84
+179.78%
3.52
Investments And Advances
—
0.00
-100.00%
0.47
0.00
Long Term Equity Investment
—
0.00
-100.00%
0.47
0.00
Other Non Current Assets
23.13
+537.28%
3.63
+9.97%
3.30
+146.64%
1.34
Total Liabilities Net Minority Interest
134.17
+22.21%
109.79
+14.07%
96.25
+168.49%
35.85
Current Liabilities
85.07
+42.54%
59.68
+35.82%
43.94
+58.50%
27.72
Payables And Accrued Expenses
41.77
+94.56%
21.47
-7.45%
23.20
+51.10%
15.35
Payables
22.61
+286.31%
5.85
-10.61%
6.55
-4.87%
6.88
Accounts Payable
22.61
+286.31%
5.85
-10.61%
6.55
-4.87%
6.88
Current Accrued Expenses
19.16
+22.69%
15.62
-6.20%
16.65
+96.60%
8.47
Pensionand Other Post Retirement Benefit Plans Current
35.58
+23.16%
28.89
+98.99%
14.52
+59.86%
9.08
Current Debt And Capital Lease Obligation
6.49
-9.27%
7.15
+71.39%
4.17
+297.05%
1.05
Current Capital Lease Obligation
6.49
-9.27%
7.15
+71.39%
4.17
+297.05%
1.05
Current Deferred Liabilities
1.24
-43.24%
2.18
+5.84%
2.06
-8.21%
2.24
Current Deferred Revenue
1.24
-43.24%
2.18
+5.84%
2.06
-8.21%
2.24
Other Current Liabilities
—
—
—
1.05
Total Non Current Liabilities Net Minority Interest
49.10
-2.00%
50.10
-4.21%
52.30
+543.75%
8.12
Long Term Debt And Capital Lease Obligation
42.05
-5.65%
44.57
-6.28%
47.55
+2249.56%
2.02
Long Term Capital Lease Obligation
42.05
-5.65%
44.57
-6.28%
47.55
+2249.56%
2.02
Non Current Deferred Liabilities
3.81
-19.01%
4.70
-0.97%
4.75
-22.14%
6.10
Non Current Deferred Revenue
3.81
-19.01%
4.70
-0.97%
4.75
-22.14%
6.10
Other Non Current Liabilities
3.24
+290.83%
0.83
—
—
Stockholders Equity
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Common Stock Equity
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Capital Stock
2,407.76
+5.79%
2,275.95
+90.96%
1,191.83
+56.94%
759.43
Common Stock
2,407.76
+5.79%
2,275.95
+90.96%
1,191.83
+56.94%
759.43
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
95.58
+2.85%
92.93
+36.31%
68.17
+26.54%
53.88
Ordinary Shares Number
95.58
+2.85%
92.93
+36.31%
68.17
+26.54%
53.88
Retained Earnings
-1,417.43
-48.87%
-952.11
-45.65%
-653.70
-48.85%
-439.17
Gains Losses Not Affecting Retained Earnings
1.86
+93.67%
0.96
-1.43%
0.98
+124.85%
-3.93
Other Equity Adjustments
1.86
+93.67%
0.96
-1.43%
0.98
+124.85%
-3.93
Total Equity Gross Minority Interest
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Total Capitalization
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Working Capital
963.27
-26.79%
1,315.70
+148.15%
530.21
+67.02%
317.46
Invested Capital
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Total Debt
48.54
-6.15%
51.72
-0.01%
51.73
+1582.21%
3.08
Capital Lease Obligations
48.54
-6.15%
51.72
-0.01%
51.73
+1582.21%
3.08
Net Tangible Assets
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Tangible Book Value
992.08
-25.11%
1,324.81
+145.74%
539.11
+70.43%
316.33
Duefrom Related Parties Current
—
0.00
-100.00%
0.09
-33.33%
0.14
Financial Assets
—
—
0.00
-100.00%
0.67
Investmentsin Subsidiariesat Cost
—
0.00
-100.00%
0.47
0.00
Other Equity Interest
-0.11
—
—
—
Restricted Common Stock
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-377.92
-64.18%
-230.19
-36.53%
-168.60
-46.35%
-115.20
Cash Flow From Continuing Operating Activities
-377.92
-64.18%
-230.19
-36.53%
-168.60
-46.35%
-115.20
Net Income From Continuing Operations
-465.32
-55.93%
-298.41
-39.10%
-214.53
-30.88%
-163.92
Depreciation Amortization Depletion
3.89
+39.68%
2.79
+153.64%
1.10
+11.70%
0.98
Depreciation And Amortization
3.89
+39.68%
2.79
+153.64%
1.10
+11.70%
0.98
Other Non Cash Items
3.01
-0.92%
3.04
+485.06%
-0.79
-294.58%
0.41
Stock Based Compensation
91.02
+31.18%
69.39
+69.49%
40.94
+44.82%
28.27
Operating Gains Losses
0.05
-90.40%
0.52
-89.99%
5.20
+1169.27%
0.41
Gain Loss On Investment Securities
—
—
—
-0.60
Gain Loss On Sale Of PPE
0.05
-1.96%
0.05
+750.00%
0.01
0.00
Change In Working Capital
4.84
-34.66%
7.41
+28.82%
5.75
-69.09%
18.61
Change In Receivables
-0.59
0.00
0.00
-100.00%
10.99
Changes In Account Receivables
-0.59
0.00
0.00
-100.00%
10.99
Change In Inventory
-2.02
0.00
0.00
—
Change In Prepaid Assets
-16.51
-176.38%
-5.97
-32.08%
-4.52
-2203.72%
0.21
Change In Payables And Accrued Expense
28.98
+117.64%
13.32
+7.77%
12.36
—
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
-1.83
-2579.73%
0.07
+104.82%
-1.53
-118.40%
8.34
Change In Other Current Liabilities
-3.18
-52916.67%
-0.01
+98.90%
-0.55
+41.79%
-0.94
Investing Cash Flow
173.91
+130.25%
-574.82
-186.82%
-200.41
-15.19%
-173.98
Cash Flow From Continuing Investing Activities
173.91
+130.25%
-574.82
-186.82%
-200.41
-15.19%
-173.98
Net PPE Purchase And Sale
-5.76
-49.90%
-3.84
+18.00%
-4.69
-183.09%
-1.66
Purchase Of PPE
-5.76
-49.90%
-3.84
+18.00%
-4.69
-183.09%
-1.66
Capital Expenditure
-5.76
-49.90%
-3.84
+18.00%
-4.69
-183.09%
-1.66
Net Investment Purchase And Sale
179.67
+131.47%
-570.97
-191.72%
-195.72
-13.58%
-172.32
Purchase Of Investment
-1,004.43
+12.41%
-1,146.77
-115.21%
-532.86
-61.56%
-329.82
Sale Of Investment
1,184.10
+105.64%
575.80
+70.79%
337.13
+114.06%
157.49
Financing Cash Flow
40.61
-96.00%
1,014.66
+159.35%
391.24
+220.78%
121.96
Cash Flow From Continuing Financing Activities
40.61
-96.00%
1,014.66
+159.35%
391.24
+220.78%
121.96
Net Common Stock Issuance
0.00
-100.00%
970.05
+162.87%
369.02
+214.75%
117.24
Common Stock Payments
0.00
+100.00%
-14.98
-2669.32%
-0.54
—
Repurchase Of Capital Stock
0.00
+100.00%
-14.98
-2669.32%
-0.54
—
Proceeds From Stock Option Exercised
40.61
-8.97%
44.61
+100.81%
22.22
+370.58%
4.72
Changes In Cash
-163.40
-177.94%
209.65
+843.34%
22.22
+113.29%
-167.22
Effect Of Exchange Rate Changes
-0.11
0.00
0.00
—
Beginning Cash Position
265.85
+373.06%
56.20
+65.42%
33.97
-83.11%
201.19
End Cash Position
102.34
-61.51%
265.85
+373.06%
56.20
+65.42%
33.97
Free Cash Flow
-383.68
-63.94%
-234.04
-35.06%
-173.29
-48.28%
-116.86
Amortization Of Securities
-15.43
-3.31%
-14.93
-138.10%
-6.27
-18544.12%
0.03
Common Stock Issuance
0.00
-100.00%
985.03
+166.54%
369.56
+215.21%
117.24
Earnings Losses From Equity Investments
0.00
-100.00%
0.47
-90.96%
5.20
+414.65%
1.01
Issuance Of Capital Stock
0.00
-100.00%
985.03
+166.54%
369.56
+215.21%
117.24
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category